Clearpoint Neuro Inc is trading at $17.30 (+29.65%) today after its partner UniQure announced positive FDA feedback for its Huntington's disease therapy, AMT-130. - The FDA agreed that 3-year Phase I/II study data for AMT-130 could support a Biologics License Application (BLA) for accelerated approval. - Clearpoint Neuro's navigation system and SmartFlow cannula are critical for administering UniQure's AMT-130 therapy. - This regulatory milestone for a key partner product highlights the value and potential broader adoption of Clearpoint Neuro's neurosurgical technologies.